非甾体类盐皮质激素受体拮抗剂治疗糖尿病肾病新进展  

New advances in the treatment of diabetic kidney disease with non-steroidal corticosteroid receptor antagonist

作　　者：张忠银[1] 胡廷婷[1] 胡晨吉 蒋林珊 王欣怡[1] ZHANG Zhongyin;HU Tingting;HU Chenji;JIANG Linshan;WANG Xinyi(Department of Pharmacy,Faculty of Clinical Pharmacy,West China Hospital,Chengdu 610041,Sichuan Province,China)

机构地区：[1]四川大学华西医院临床药学部药剂科,四川成都610041

出　　处：《世界临床药物》2024年第12期1309-1313,共5页World Clinical Drug

摘　　要：糖尿病肾病(diabetic kidney disease,DKD)是一种由糖尿病(diabetes mellitus)引发的肾脏疾病,严重影响患者生活质量,对全球卫生经济亦造成重大负担。非甾体类盐皮质激素受体拮抗剂(mineralocorticoid receptor antagonist,MRA)是一种DKD治疗新型药物,在降低心血管事件、延缓肾功能恶化方面具有潜力。较传统DKD治疗药物,非甾体类MRA可更有效地减缓炎症反应和组织纤维化过程,同时降低高钾血症(hyperpotassemia)发生率。现综述最新非甾体类MRA用于DKD疗效进展,旨在为DKD患者提供更安全、有效的治疗选择。Diabetic kidney disease(DKD)is a type of kidney disease caused by diabetes mellitus,which seriously affects the quality of life of patients and poses a major burden on the global health economy.Non-steroidal corticosteroid receptor antagonist(MRA)is a novel drug for the treatment of DKD,which has the potential to reduce cardiovascular events and delay the deterioration of renal function.Compared with traditional DKD agents,non-steroidal MRA can more effectively slow down the inflammatory reaction and fibrotic processes,and reduce the incidence of hyperkalemia.This article reviewed the recent progress of non-steroidal MRA's efficacy in DKD,aiming to provide safer and more effective treatment options for DKD patients.

关 键 词：非甾体盐皮质激素受体拮抗剂 糖尿病肾病 非奈利酮 

分 类 号：R587.2[医药卫生—内分泌] R692.9[医药卫生—内科学]